-
公开(公告)号：US07998924B2
公开(公告)日：2011-08-16
申请号：US12758435
申请日：2010-04-12
Applicant: Mark I. Greene , Ramachandran Murali , Alan Berezov
Inventor： Mark I. Greene , Ramachandran Murali , Alan Berezov
CPC classification number: C07K16/32 , A61K2039/505 , C07K2317/565
Abstract: Novel peptides and pharmaceutical compositions comprising the same are disclosed. Conjugated compositions peptides linked to detectable agents and/or cytotoxic agents are disclosed. Method of detecting tumors that have p185 on tumor cell surfaces are disclosed. Methods of preventing transformation of a normal cell into a tumor cell in an individual at risk of developing a tumor having tumor cells which have p185 on their surfaces are disclosed. Methods of treating an individual who has cancer characterized by tumor cells that have a p185 on their cell surfaces are disclosed.
Abstract translation: 公开了包含其的新型肽和药物组合物。 公开了与可检测的试剂和/或细胞毒性剂连接的共轭组合物肽。 公开了检测肿瘤细胞表面上具有p185的肿瘤的方法。 公开了防止正常细胞转化成具有在其表面具有p185的肿瘤细胞的肿瘤的风险中的个体的肿瘤细胞的方法。 公开了在细胞表面处理具有p185的肿瘤细胞特征的癌症的个体的方法。
-
公开(公告)号：US07906624B2
公开(公告)日：2011-03-15
申请号：US10589688
申请日：2005-02-18
Applicant: Mark I. Greene , Ramachandran Murali , Hongtao Zhang
Inventor： Mark I. Greene , Ramachandran Murali , Hongtao Zhang
CPC classification number: C07K14/36 , C07K14/4746 , C07K14/522 , C07K2317/565 , C07K2319/70 , C12N9/0089 , Y10S530/808
Abstract: A multimeric peptidomimetic that comprises two or more monomers is disclosed. The monomers comprise an exocyclic peptide comprising a ring structure, a flexible linker sequence and a multimeric motif. Use of the monomers, a nucleic acid molecule encoding monomers, recombinant expression vectors comprising the nucleic acid molecule and host cells comprising a recombinant expression vector are disclosed. Methods of delivering a drug, a toxin, a nucleic acid molecule, a radionuclide or a detectable compound to a cell are disclosed.
Abstract translation: 公开了包含两种或多种单体的多聚体拟肽。 单体包含包含环结构，柔性接头序列和多聚体基序的环外肽。 公开了使用单体，编码单体的核酸分子，包含核酸分子的重组表达载体和包含重组表达载体的宿主细胞。 公开了将药物，毒素，核酸分子，放射性核素或可检测化合物递送至细胞的方法。
-
公开(公告)号：US20090221527A1
公开(公告)日：2009-09-03
申请号：US11815134
申请日：2006-01-31
Applicant: Mark I. Greene , Ramachandran Murali , Xin Cheng , Raphael Ottenbrite , Yingxin Xiao
Inventor： Mark I. Greene , Ramachandran Murali , Xin Cheng , Raphael Ottenbrite , Yingxin Xiao
IPC: A61K31/69 , C07C59/31 , C07C69/353 , C07D311/82 , C07C241/00 , A61K31/09 , A61K31/216 , A61K31/222 , A61K31/352 , A61K31/15 , C07C215/20 , A61K31/135 , C07C69/76 , A61K31/225 , C07C41/01 , C07F5/02 , C07D209/12 , A61K31/405 , C07D311/94
CPC classification number: C07D493/10 , A61K31/15 , A61K31/352 , A61K31/365 , C07C251/86 , C07D311/82
Abstract: The present invention is directed to compounds that are allosteric inhibitors of tumor necrosis factor receptor I, compositions comprising such compounds, and methods of using such compounds and compositions thereof in the treatment of TNF-α mediated conditions.
Abstract translation: 本发明涉及作为肿瘤坏死因子受体I的变构抑制剂的化合物，包含这些化合物的组合物，以及使用这些化合物及其组合物治疗TNF-α介导的病症的方法。
-
公开(公告)号：US07288519B2
公开(公告)日：2007-10-30
申请号：US10445399
申请日：2003-05-23
Applicant: Mark I. Greene , Ramachandran Murali , Akihiro Hasegawa
Inventor： Mark I. Greene , Ramachandran Murali , Akihiro Hasegawa
CPC classification number: C07K14/70578 , A61K38/00
Abstract: Exocyclic peptide mimetics that disable Fas were developed. A three dimensional model of the Fas receptor-ligand complex was constructed and structurally predicted regions of the receptor that were relevant to binding ligand were used to create constrained peptide mimetics. Exocyclic anti-Fas peptide mimetics were identified that block Fas receptor-ligand interactions, and modulate Fas biological activity both in vitro and in vivo. The mimetics are useful, e.g., for treating Fas-related pathologies.
Abstract translation: 开发了禁用Fas的外来肽模拟物。 构建了Fas受体 - 配体复合物的三维模型，并且结构上预测与结合配体相关的受体区域用于产生约束肽模拟物。 鉴定了外环抗Fas肽模拟物阻断Fas受体 - 配体相互作用，并在体外和体内调节Fas生物活性。 模拟物可用于例如治疗Fas相关病理学。
-
公开(公告)号：US06417168B1
公开(公告)日：2002-07-09
申请号：US09111681
申请日：1998-07-08
Applicant: Mark I. Greene , Donald M. O'Rourke , Ramachandran Murali , Byeong-Woo Park
Inventor： Mark I. Greene , Donald M. O'Rourke , Ramachandran Murali , Byeong-Woo Park
IPC: A01N4304
CPC classification number: C07K16/32 , A61K38/1709 , A61K39/39558 , A61K45/06 , A61K48/00 , A61K2039/505 , A61K2039/507 , A61K2039/572 , A61N5/10 , C07K14/71 , C07K2317/24 , C07K2317/73 , A61K2300/00
Abstract: Methods of treating an individual who has an erbB protein mediated tumor is disclosed. Methods of preventing erbB protein mediated tumors in an individual are disclosed. The methods comprise administering to the individual a nucleic acid molecule that encodes a protein that dimerizes with an erbB protein and that is deficient in tyrosine kinase activity. Composition that comprise such nucleic acid molecules including pharmaceutical compositions are disclosed.
Abstract translation: 公开了治疗患有erbB蛋白介导的肿瘤的个体的方法。 公开了预防个体中erbB蛋白介导的肿瘤的方法。 所述方法包括向个体施用编码与erbB蛋白二聚化并且缺乏酪氨酸激酶活性的蛋白质的核酸分子。 公开了包含这种核酸分子（包括药物组合物）的组合物。
-
Patent Agency Ranking26.发明授权
公开(公告)号：US5637677A
公开(公告)日：1997-06-10
申请号：US940654
申请日：1992-09-03
Applicant: Mark I. Greene , William V. Williams , David B. Weiner , Jeffrey A. Cohen , Thomas Kieber-Emmons , Robert M. Williams
Inventor： Mark I. Greene , William V. Williams , David B. Weiner , Jeffrey A. Cohen , Thomas Kieber-Emmons , Robert M. Williams
IPC: A61K39/00 , C07K14/005 , C07K14/14 , C07K14/16 , C07K14/725 , C07K14/73 , C07K14/74 , C07K16/10 , C07K7/00
CPC classification number: C07K14/005 , C07K14/7051 , C07K14/70514 , C07K14/70539 , C07K16/10 , C07K16/1063 , A61K39/00 , C12N2720/12022 , C12N2740/16122
Abstract: A method of constructing biologically active compounds which mimic the biological activity of the biologically active protein or which block the activity of the biologically active protein is disclosed. A method of identifying specific and discrete portions of pathogen antigens which either serve as epitopes for neutralizing antibodies or which are involved in pathogen binding to host cell receptors is disclosed. A method of constructing biologically active compounds which compete with cellular receptors for binding to either biologically active proteins or pathogen antigens is disclosed.
Abstract translation: 公开了一种构建模拟生物活性蛋白的生物活性或阻断生物活性蛋白的活性的生物活性化合物的方法。 公开了鉴定作为中和抗体或参与病原体与宿主细胞受体结合的表位的病原体抗原的特异性和离散部分的方法。 公开了一种构建与细胞受体竞争结合生物活性蛋白或病原体抗原的生物活性化合物的方法。
-
公开(公告)号：US5574009A
公开(公告)日：1996-11-12
申请号：US326817
申请日：1994-10-20
Applicant: Jeffrey A. Cohen , Mark I. Greene , William V. Williams
Inventor： Jeffrey A. Cohen , Mark I. Greene , William V. Williams
CPC classification number: C07K14/705 , C07K16/28 , A61K38/00
Abstract: The present invention provides methods for treating mammalian diseases and conditions characterized by myelin destruction. The present invention provides methods for inducing myelin formation by myelin forming cells expressing reovirus type 3 receptors comprising administering to such cells an effective amount of a compound bindable with the reovirus type 3 receptor. The compounds for use in the method of the invention preferably comprise antibodies and peptides, more preferably synthetic peptides.
Abstract translation: 本发明提供治疗哺乳动物疾病和以髓鞘破坏为特征的病症的方法。 本发明提供了通过表达呼肠
病病毒3型受体的髓鞘形成细胞诱导髓磷脂形成的方法，其包括向所述细胞施用有效量的与呼肠
念珠菌3型受体结合的化合物。 用于本发明方法的化合物优选包含抗体和肽，更优选合成肽。-
公开(公告)号：US09133270B2
公开(公告)日：2015-09-15
申请号：US14003989
申请日：2012-03-08
Applicant: Mark I. Greene , Hongtao Zhang
Inventor： Mark I. Greene , Hongtao Zhang
CPC classification number: C07K16/18 , A61K2039/505 , C07K7/06 , C07K16/32 , C07K2317/524 , C07K2317/72 , C07K2317/73 , C07K2317/92 , C07K2319/00 , C07K2319/21 , C07K2319/30
Abstract: Disclosed herein are recombinant protein scaffolds for use in producing antigen-binding proteins. Related antigen-binding proteins are also provided herein. In addition, nucleic acids encoding such recombinant protein scaffolds and antigen-binding proteins are also described. Vectors and cells useful for expression of the described proteins are also provided, as are methods of use.
Abstract translation: 本文公开了用于产生抗原结合蛋白的重组蛋白质支架。 本文还提供了相关抗原结合蛋白。 此外，还描述了编码这种重组蛋白支架和抗原结合蛋白的核酸。 还提供了用于表达所述蛋白质的载体和细胞，以及使用方法。
-
公开(公告)号：US20150010551A1
公开(公告)日：2015-01-08
申请号：US14485525
申请日：2014-09-12
Applicant: Mark I. Greene , Donald M. O'Rourke , Ramachandran Murali , Byeong Woo Park
Inventor： Mark I. Greene , Donald M. O'Rourke , Ramachandran Murali , Byeong Woo Park
IPC: C07K16/32 , A61K45/06 , A61N5/10 , A61K39/395
CPC classification number: C07K16/32 , A61K38/1709 , A61K39/39558 , A61K45/06 , A61K48/00 , A61K2039/505 , A61K2039/507 , A61K2039/572 , A61N5/10 , C07K14/71 , C07K2317/24 , C07K2317/73 , A61K2300/00
Abstract: Methods of treating an individual who has an erbB protein mediated tumor is disclosed. Methods of preventing erbB protein mediated tumors in an individual are disclosed. The methods comprise administering to the individual a nucleic acid molecule that encodes a protein that dimerizes with an erbB protein and that is deficient in tyrosine kinase activity. Composition that comprise such nucleic acid molecules including pharmaceutical compositions are disclosed.
-
30.发明授权Cavity induced allosteric modification of intermolecular interactions and methods of identifying compounds that effect the same 有权分子间相互作用的腔诱导变构修饰和识别影响相同的化合物的方法公开(公告)号：US08785419B2
公开(公告)日：2014-07-22
申请号：US13194832
申请日：2011-07-29
Applicant: Ramachandran Murali , Mark I. Greene
Inventor： Ramachandran Murali , Mark I. Greene
IPC: A01N33/26 , A61K31/655 , A01N43/36 , A61K31/40 , A01N37/28 , A61K31/215 , A01N47/28 , A61K31/17 , A61K8/42
CPC classification number: A61K31/655 , A61K8/42 , A61K31/17 , A61K31/40 , G01N33/573 , G01N33/68 , G01N2500/02
Abstract: Method of identifying compounds that modulate intermolecular interactions between a target protein and a modifier are disclosed. Pharmaceutical composition comprising compounds that inhibit intermolecular interactions between a target protein and a modifier are disclosed. Methods of treating individual suffering from inflammatory conditions, undesirable immune responses, immunological conditions and bacterial infections are disclosed.
Abstract translation: 公开了鉴定调节靶蛋白和修饰剂之间的分子间相互作用的化合物的方法。 公开了包含抑制靶蛋白和修饰剂之间的分子间相互作用的化合物的药物组合物。 公开了治疗患有炎性病症，不良免疫应答，免疫学条件和细菌感染的个体的方法。
-
-
-
-
-
-
-
-
-
Search Results
90
records
(took 0.036 seconds)
